Stockscreener 앱 받기
4.05
2.41%
-0.10
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
BNP Paribas Financial Markets Purchases 6,764 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Cough in Idiopathic Pulmonary Pipeline Report 2024: Clinical Trials Progress and Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - The Eastern Progress Online
Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75% - MSN
Trevi Therapeutics sets $50 million stock offering price By Investing.com - Investing.com Australia
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - The Eastern Progress Online
Form 424B5 Trevi Therapeutics, Inc. - StreetInsider.com
Trevi Therapeutics Prices of $50 Million Underwritten Offering - citybiz
Trevi Therapeutics sets $50 million stock offering price - Investing.com
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering - PR Newswire
Trevi Therapeutics (TRVI) Gains Market Traction After Positive Trial Results - Stocks Telegraph
Institutional investors control 39% of Trevi Therapeutics, Inc. (NASDAQ:TRVI) and were rewarded last week after stock increased 38% - Simply Wall St
Trevi stock rockets on Haduvio study update - MSN
Trevi stock rockets on Haduvio study update (TRVI:NASDAQ) - Seeking Alpha
Trevi Therapeutics stock soars to 52-week high of $4.07 - Investing.com
Trevi Therapeutics Shares Hit 52-Week High After Positive Trial Analysis - MarketWatch
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? - Benzinga
Trevi Therapeutics, Inc. Announces Positive Outcome from Sample Size Re-Estimation Resulting in No Change to the Current Sample Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - Marketscreener.com
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - PR Newswire
Trevi Therapeutics' Phase 2b CORAL Trial Hits Key Milestone with Strong Interim Analysis - StockTitan
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - The Eastern Progress Online
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.13 Consensus Target Price from Brokerages - Defense World
Trevi Therapeutics to Participate in September Investor and Medical Conferences - The Eastern Progress Online
HC Wainwright Has Negative Outlook of TRVI FY2024 Earnings - MarketBeat
HC Wainwright Predicts Lower Earnings for Trevi Therapeutics - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough - The Eastern Progress Online
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program - The Eastern Progress Online
D. Boral Capital Reiterates Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Trevi stock tumbles 23% amid Haduvio study results - MSN
Companies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In Growth - Yahoo Finance
Trevi Therapeutics Reports Positive Results for Human-Abuse Potential of Oral Nalbuphine - MarketWatch
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine - GuruFocus.com
Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap - The Globe and Mail
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Fina - GuruFocus.com
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GuruFocus.com
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - PR Newswire
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference – Company Announcement - Financial Times
Trevi Therapeutics to Participate in Upcoming April Events - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Consensus Target Price from Brokerages - Defense World
Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Quantisnow
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Average PT from Brokerages - MarketBeat
How Do Things Look For Trevi Therapeutics Inc (NASDAQ: TRVI) In The Short-Term? - Stocks Register
Trevi Therapeutics Announces Proposed Public Offering - Quantisnow
Trevi Therapeutics to Participate in Upcoming September Events - Quantisnow
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Quantisnow
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences - Quantisnow
FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs - MarketBeat
2.88%
2.65%
자본화:
|
볼륨(24시간):